[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Tony_Calles Dr. Antonio Calles ๐ซ๐ญ Dr. Antonio Calles ๐ซ๐ญ posts on X about alk, changer, mtd, stg the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::2155543177/interactions)  - X Week XXXXXX +636,250% - X Month XXXXXX +141% - X Months XXXXXX +38% - X Year XXXXXX -XX% ### Mentions: XX [#](/creator/twitter::2155543177/posts_active)  - X Week XX +1,200% - X Month XX +160% - X Months XX +110% - X Year XX +26% ### Followers: XXXXXX [#](/creator/twitter::2155543177/followers)  - X Week XXXXXX +0.31% - X Month XXXXXX +0.47% - X Months XXXXXX +2.50% - X Year XXXXXX +2.70% ### CreatorRank: XXXXXXX [#](/creator/twitter::2155543177/influencer_rank)  ### Social Influence [#](/creator/twitter::2155543177/influence) --- **Social topic influence** [alk](/topic/alk) #14, [changer](/topic/changer), [mtd](/topic/mtd), [stg](/topic/stg) ### Top Social Posts [#](/creator/twitter::2155543177/posts) --- Top posts by engagements in the last XX hours "๐ฐ X minutes subcutaneous administration of pembrolizumab every X weeks is a game changer. ๐Berahyaluronidase alfa (MK-5180 Alteogen Inc.) acts as a permeation enhancer that temporarily degrades hyaluronan in the extracellular matrix surrounding the injection area increasing dispersion and enabling subcutaneous administration of pembrolizumab. @EnriquetaFelip brilliantly presented Phase III MK-3475A-D77 trial with simultaneous publication @Annals_Oncology @myESMO #ESMOAmbassadors #ELCC25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1905285069775778172) [@Tony_Calles](/creator/x/Tony_Calles) 2025-03-27T15:45Z 12.1K followers, 6872 engagements "MDT-BRIDGE broaden the population finally considered for surgery in borderline resectable NSCLC with just X cycles of neoadjuvant chemo-Durva. XX% pCR with acceptable surgical outcomes. @MartinReck2 showed the importance of longitudinal MTD decisions #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1979450110602858918) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-18T07:30Z 12.1K followers, 1865 engagements "๐ Zongertinib update from Beamion Lung1. ๐ฅ Impressive results in HER2 mutant treatment-naive patients. ORR XX% for a TKI is the highest for this difficult to treat populations. Congratulations @DrSanjayPopat for the nice presentation ๐ Randomized Phase X trial BeamionLung02 ongoing and awaiting results. #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1979196571162980379) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-17T14:43Z 12.1K followers, 2120 engagements "Pasi Janne presents overall survival by prognostic factors in FLAURA-2 trial of Osimertinib + chemo vs osi alone. Nicely summarized in his last slide. #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1979203247656071665) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-17T15:10Z 12.1K followers, 7015 engagements "Median overall survival for newly diagnosed metastasic ALK+ lung cancer patient treated with alectinib is . ๐ฅ XX months #ESMO25 #LCSM @TonyMok9 ALEX trial" [X Link](https://x.com/Tony_Calles/status/1979205080436867120) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-17T15:17Z 12.1K followers, 9706 engagements "Brigatinib after alectinib in ALK+ NSCLC. Activity regardless of ALK secondary mutation. Practice informing data. #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1979799422759497891) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-19T06:38Z 12.1K followers, 2538 engagements "๐ Zipalaternib brain efficacy in patients with EGFR exon XX mutation ๐ง ORR similar to systemic 5/16 (31.3%) patients with measurable CNS disease - 2/5 responders also had LMD at baseline #ESMO25 #LCSM @Exon20Group" [X Link](https://x.com/Tony_Calles/status/1979806355256172686) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-19T07:06Z 12.1K followers, 1205 engagements "๐ฅ HARMONi-6: Ivonescimab + chemo vs. Tislelizumab + chemo in stage IIIB-IV Squamous NSCLC. PFS improvement by X months (11 vs 7; HR 0.6) Activity in all PD-L1 subgroups including PD-L11% No safety concerns by anti-VEGF component OS not mature yet. New SoC #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1979920816549630446) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-19T14:41Z 12.1K followers, 23.3K engagements "ARTEMIDE-01 Rilvegostomig an anti-PD-1/TIGIT bispecific antibody in 1st line NSCLC. Another anti-TIGIT jumping in the pool without looking at the water. #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1980192999804998017) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-20T08:42Z 12.1K followers, 1190 engagements "TeLuRide-005: Phase Il study of EIK1001 a toll-like receptor 7/8 (TLR7/8) co-agonist with pembrolizumab + chemotherapy in 1L Stg IV NSCLC ๐ขCSR XX% mostly G1-2 ๐กHard to separate the contribution of TLR7/8 in efficacy from chemo-IO without a control arm. Phase X trial planned. #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1980197621840109674) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-20T09:01Z 12.1K followers, XXX engagements "PAULIEN Open-label phase Ill randomized trial ๐ฅ Pembrolizumab + chemotherapy vs pembro alone in PD-L1 XX% NSCLC Halted due to futility. No differences seen on PFS or OS. More toxic with chemo. Food for thought now we are starting to have prospective data to this relevant clinical question. #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1980200952771543121) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-20T09:14Z 12.1K followers, 4770 engagements "ELEVATE trial ๐ Ensartinib as adjuvant therapy in stage IB-IIIB ALK+ NSCLC. Positive for DFS. No OS provided. Previous chemo adjuvant allowed but intriguingly not significant for PFS in the forest plot (provide pic if you got it please. I missed it) #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1980255811990413820) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-20T12:52Z 12.1K followers, XXX engagements "5 year OS of adjuvant alectinib in ALK+ NSCLC ๐ No you are not in the breast cancer session room as Dr. Dziadziuszko noted. #ESMO25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1980257255099334910) [@Tony_Calles](/creator/x/Tony_Calles) 2025-10-20T12:58Z 12.1K followers, 2420 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Dr. Antonio Calles ๐ซ๐ญ posts on X about alk, changer, mtd, stg the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Social topic influence alk #14, changer, mtd, stg
Top posts by engagements in the last XX hours
"๐ฐ X minutes subcutaneous administration of pembrolizumab every X weeks is a game changer. ๐Berahyaluronidase alfa (MK-5180 Alteogen Inc.) acts as a permeation enhancer that temporarily degrades hyaluronan in the extracellular matrix surrounding the injection area increasing dispersion and enabling subcutaneous administration of pembrolizumab. @EnriquetaFelip brilliantly presented Phase III MK-3475A-D77 trial with simultaneous publication @Annals_Oncology @myESMO #ESMOAmbassadors #ELCC25 #LCSM"
X Link @Tony_Calles 2025-03-27T15:45Z 12.1K followers, 6872 engagements
"MDT-BRIDGE broaden the population finally considered for surgery in borderline resectable NSCLC with just X cycles of neoadjuvant chemo-Durva. XX% pCR with acceptable surgical outcomes. @MartinReck2 showed the importance of longitudinal MTD decisions #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-18T07:30Z 12.1K followers, 1865 engagements
"๐ Zongertinib update from Beamion Lung1. ๐ฅ Impressive results in HER2 mutant treatment-naive patients. ORR XX% for a TKI is the highest for this difficult to treat populations. Congratulations @DrSanjayPopat for the nice presentation ๐ Randomized Phase X trial BeamionLung02 ongoing and awaiting results. #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-17T14:43Z 12.1K followers, 2120 engagements
"Pasi Janne presents overall survival by prognostic factors in FLAURA-2 trial of Osimertinib + chemo vs osi alone. Nicely summarized in his last slide. #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-17T15:10Z 12.1K followers, 7015 engagements
"Median overall survival for newly diagnosed metastasic ALK+ lung cancer patient treated with alectinib is . ๐ฅ XX months #ESMO25 #LCSM @TonyMok9 ALEX trial"
X Link @Tony_Calles 2025-10-17T15:17Z 12.1K followers, 9706 engagements
"Brigatinib after alectinib in ALK+ NSCLC. Activity regardless of ALK secondary mutation. Practice informing data. #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-19T06:38Z 12.1K followers, 2538 engagements
"๐ Zipalaternib brain efficacy in patients with EGFR exon XX mutation ๐ง ORR similar to systemic 5/16 (31.3%) patients with measurable CNS disease - 2/5 responders also had LMD at baseline #ESMO25 #LCSM @Exon20Group"
X Link @Tony_Calles 2025-10-19T07:06Z 12.1K followers, 1205 engagements
"๐ฅ HARMONi-6: Ivonescimab + chemo vs. Tislelizumab + chemo in stage IIIB-IV Squamous NSCLC. PFS improvement by X months (11 vs 7; HR 0.6) Activity in all PD-L1 subgroups including PD-L11% No safety concerns by anti-VEGF component OS not mature yet. New SoC #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-19T14:41Z 12.1K followers, 23.3K engagements
"ARTEMIDE-01 Rilvegostomig an anti-PD-1/TIGIT bispecific antibody in 1st line NSCLC. Another anti-TIGIT jumping in the pool without looking at the water. #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-20T08:42Z 12.1K followers, 1190 engagements
"TeLuRide-005: Phase Il study of EIK1001 a toll-like receptor 7/8 (TLR7/8) co-agonist with pembrolizumab + chemotherapy in 1L Stg IV NSCLC ๐ขCSR XX% mostly G1-2 ๐กHard to separate the contribution of TLR7/8 in efficacy from chemo-IO without a control arm. Phase X trial planned. #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-20T09:01Z 12.1K followers, XXX engagements
"PAULIEN Open-label phase Ill randomized trial ๐ฅ Pembrolizumab + chemotherapy vs pembro alone in PD-L1 XX% NSCLC Halted due to futility. No differences seen on PFS or OS. More toxic with chemo. Food for thought now we are starting to have prospective data to this relevant clinical question. #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-20T09:14Z 12.1K followers, 4770 engagements
"ELEVATE trial ๐ Ensartinib as adjuvant therapy in stage IB-IIIB ALK+ NSCLC. Positive for DFS. No OS provided. Previous chemo adjuvant allowed but intriguingly not significant for PFS in the forest plot (provide pic if you got it please. I missed it) #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-20T12:52Z 12.1K followers, XXX engagements
"5 year OS of adjuvant alectinib in ALK+ NSCLC ๐ No you are not in the breast cancer session room as Dr. Dziadziuszko noted. #ESMO25 #LCSM"
X Link @Tony_Calles 2025-10-20T12:58Z 12.1K followers, 2420 engagements
/creator/x::Tony_Calles